{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361699994191585152.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1111/j.1365-2036.2006.02731.x"}},{"identifier":{"@type":"URI","@value":"http://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2036.2006.02731.x"}},{"identifier":{"@type":"URI","@value":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-2036.2006.02731.x"}}],"dc:title":[{"@value":"A partially overlapping treatment course with lamivudine and interferon in hepatitis B e antigen‐negative chronic hepatitis B"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:sec><jats:title>Summary</jats:title></jats:sec><jats:sec><jats:title>Background</jats:title><jats:p>Treatment of patients with hepatitis B e antigen (HBeAg)‐negative chronic hepatitis B (CHBe‐) with interferon or lamivudine alone is inefficient and reports of combination treatment with both drugs, equivocal so far.</jats:p></jats:sec><jats:sec><jats:title>Aim</jats:title><jats:p>To investigate the efficacy of a lamivudine–interferon combination therapy in 36 patients HBeAg‐negative CHBe−.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Lamivudine was administered from 1 to 12 months and interferon‐<jats:italic>α</jats:italic>2b from 7 to 18 months. A historical control group of 36 CHBe− patients, matched for age and sex and treated with the same dosage of interferon‐<jats:italic>α</jats:italic>2b was used. All patients were followed up for ≥12‐month post‐treatment.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>The biochemical response rate at the end of treatment was 78% in lamivudine–interferon and 52.8% in interferon–control group (<jats:italic>P</jats:italic> = 0.026) and at 12‐month post‐treatment 38.9% and 22.2%, respectively (<jats:italic>P</jats:italic> = 0.125). Alanine aminotransferase normalization and serum HBV‐DNA levels ≤30 000 cp/mL were observed in 50.0% of lamivudine–interferon‐treated and 30.6% of interferon‐treated patients at the end of treatment (<jats:italic>P</jats:italic> =0.093) and in 22.2% and 13.9% of patients, respectively, at 12‐month post‐treatment (<jats:italic>P</jats:italic> = 0.358). Moreover, alanine aminotransferase normalization and undetectable serum HBV‐DNA (<400 cp/mL) was observed in 30.6% of lamivudine–interferon‐treated and 8.3% of interferon‐treated patients at the end of treatment (<jats:italic>P</jats:italic> = 0.017) and in 8.3% and 0% of patients, respectively, at 12‐month post‐treatment (<jats:italic>P</jats:italic> = 0.076).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>In CHBe−, 12 months after ending a lamivudine–interferon partially overlapping 18‐month combination course, 22% of patients still maintain normal alanine aminotransferase and HBV‐DNA levels ≤30 000 cp/mL. However, a 12‐month interferon monotherapy course may achieve similar responses.</jats:p></jats:sec>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380285706236945545","@type":"Researcher","foaf:name":[{"@value":"E. K. MANESIS"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994191585154","@type":"Researcher","foaf:name":[{"@value":"G. V. PAPATHEODORIDIS"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994191585152","@type":"Researcher","foaf:name":[{"@value":"S. J. HADZIYANNIS"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"02692813"},{"@type":"EISSN","@value":"13652036"}],"prism:publicationName":[{"@value":"Alimentary Pharmacology & Therapeutics"}],"dc:publisher":[{"@value":"Wiley"}],"prism:publicationDate":"2005-12-13","prism:volume":"23","prism:number":"1","prism:startingPage":"99","prism:endingPage":"106"},"reviewed":"false","dc:rights":["http://onlinelibrary.wiley.com/termsAndConditions#vor"],"url":[{"@id":"http://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2036.2006.02731.x"},{"@id":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-2036.2006.02731.x"}],"createdAt":"2005-12-13","modifiedAt":"2023-10-13","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Pharmacology%20(medical)","dc:title":"Pharmacology (medical)"},{"@id":"https://cir.nii.ac.jp/all?q=Gastroenterology","dc:title":"Gastroenterology"},{"@id":"https://cir.nii.ac.jp/all?q=Hepatology","dc:title":"Hepatology"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050022476722646656","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Sequential therapy involving an early switch from entecavir to pegylated interferon-α in Japanese patients with chronic hepatitis B"},{"@language":"ja-Kana","@value":"ニホンジン マンセイ Bガタ カンエン カンジャ ニオケル エンテカビル カラ ペグインターフェロンα エノ ソウキ キリカエ オ トモナウ チクジ リョウホウ"},{"@language":"ja","@value":"日本人慢性B型肝炎患者における、エンテカビルからペグインターフェロンαへの早期切り替えを伴う逐次療法"},{"@value":"Sequential therapy involving an early switch from entecavir to pegylated interferon‐α in Japanese patients with chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004235757163264","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009"}]},{"@id":"https://cir.nii.ac.jp/crid/1360283693139692416","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Factors associated with the effect of interferon‐α sequential therapy in order to discontinue nucleoside/nucleotide analog treatment in patients with chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285706236945920","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B: simultaneous or sequential"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285709456608384","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Long-Term Outcome of Sequential Therapy with Lamivudine Followed by Interferon-β in Nucleoside-Naive, Hepatitis B e-Antigen-Positive Patients with Chronic Hepatitis B Virus Genotype C Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285714965416192","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Antiviral therapy for chronic hepatitis B: Combination of nucleoside analogs and interferon"}]},{"@id":"https://cir.nii.ac.jp/crid/1360290617824940288","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Pilot study of tenofovir disoproxil fumarate and pegylated interferon-alpha 2a add-on therapy in Japanese patients with chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567181214789888","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848656190200320","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Entecavir and interferon-α sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204792984064","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"日本肝臓学会コンセンサス神戸2009：C型肝炎の診断と治療"},{"@language":"en","@value":"JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis C"},{"@language":"ja-Kana","@value":"ニホン カンゾウ ガッカイ コンセンサス コウベ 2009 Cガタ カンエン ノ シンダン ト チリョウ"},{"@value":"日本肝臓学会コンセンサス神戸2009--B型肝炎の診断と治療"},{"@language":"ja-Kana","@value":"ニホン カンゾウ ガッカイ コンセンサス コウベ 2009 Bガタ カンエン ノ シンダン ト チリョウ"},{"@value":"JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1111/j.1365-2036.2006.02731.x"},{"@type":"CROSSREF","@value":"10.1111/j.1872-034x.2010.00739.x_references_DOI_GbpDWHtlqm1Km4r3fZKrwpgEsmh"},{"@type":"CROSSREF","@value":"10.1111/hepr.12488_references_DOI_GbpDWHtlqm1Km4r3fZKrwpgEsmh"},{"@type":"CROSSREF","@value":"10.1007/s00535-012-0742-5_references_DOI_GbpDWHtlqm1Km4r3fZKrwpgEsmh"},{"@type":"CROSSREF","@value":"10.1089/jir.2014.0234_references_DOI_GbpDWHtlqm1Km4r3fZKrwpgEsmh"},{"@type":"CROSSREF","@value":"10.4254/wjh.v7.i23.2427_references_DOI_GbpDWHtlqm1Km4r3fZKrwpgEsmh"},{"@type":"CROSSREF","@value":"10.2957/kanzo.51.243_references_DOI_GbpDWHtlqm1Km4r3fZKrwpgEsmh"},{"@type":"CROSSREF","@value":"10.1007/s00535-020-01707-6_references_DOI_GbpDWHtlqm1Km4r3fZKrwpgEsmh"},{"@type":"CROSSREF","@value":"10.1111/hepr.13050_references_DOI_GbpDWHtlqm1Km4r3fZKrwpgEsmh"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_GbpDWHtlqm1Km4r3fZKrwpgEsmh"},{"@type":"CROSSREF","@value":"10.1007/s00535-017-1360-z_references_DOI_GbpDWHtlqm1Km4r3fZKrwpgEsmh"},{"@type":"CROSSREF","@value":"10.1007/s00535-012-0645-5_references_DOI_GbpDWHtlqm1Km4r3fZKrwpgEsmh"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_GbpDWHtlqm1Km4r3fZKrwpgEsmh"}]}